Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment

Aims To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium‐glucose cotransporter‐1 and ‐2, in adults with type 2 diabetes (T2D) and stage 4 chronic kidney disease (CKD4). Materials and Methods This 52‐week, phase 3, randomized (1:1:1), placebo‐controlled trial evaluated sota...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2021-12, Vol.23 (12), p.2632-2642
Hauptverfasser:	Cherney, David Z. I., Ferrannini, Ele, Umpierrez, Guillermo E., Peters, Anne L., Rosenstock, Julio, Carroll, Amy K., Lapuerta, Pablo, Banks, Phillip, Agarwal, Rajiv
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events antihyperglycaemic therapy Blood pressure Body weight Clinical outcomes Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Drug Therapy, Combination Epidermal growth factor receptors Glomerular filtration rate Glycated Hemoglobin A - analysis Glycosides - therapeutic use Hemoglobin Humans Hyperglycemia Hypoglycemic Agents - adverse effects Inhibitor drugs Kidney diseases Patient safety Placebos Safety severe renal impairment SGLT2 inhibitors Side effects Sodium-glucose cotransporter sotagliflozin stage 4 chronic kidney disease Statistical analysis Treatment Outcome type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!